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Available online xxxxCommon variable immunodeﬁciency (CVID) is a heterogeneous group of diseases, characterized by primary
hypogammaglobulinemia. B and T cell abnormalities have been described in CVID. Typical clinical features of
CVID are recurrent airway infections; lymphoproliferative, autoinﬂammatory, or neoplastic disorders; and autoim-
mune diseases amongwhich autoimmune thrombocytopenia (ITP) is themost common. The coexistence of immu-
nodeﬁciency and autoimmunity appears paradoxical, since one represents a hypoimmune state and the other a
hyperimmune state. Considering both innate and adaptive immune response abnormalities in CVID, it is easier to
understand the mechanisms that lead to a breakdown of self-tolerance. CD21low B cells derive from mature B
cells that have undergone chronic immune stimulation; they are increased in CVID patients. The expansion of
CD21low B cells is also observed in certain autoimmune diseases. We have studied CD21low B cells in patients with
CVID, CVID, and ITP and with ITP only. We observed a statistically signiﬁcant increase in the CD21low population
in the three pathological groups. Moreover, we found statistical differences between the two groups of CVID pa-
tients: patients with ITP had a higher percentage of CD21low cells. Our data suggest that CD21low cells are related
to autoimmunity and may represent a link between infection and autoimmunity.
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Common variable immunodeﬁciency (CVID) is considered a hetero-
geneous group of primary immune deﬁciency diseases characterised by
reduced serum levels of IgG, IgA, and/or IgM, with decreased antibody
production and impaired antibody response to both polysaccharide
and protein antigens. Because of low antibody levels, most patients
have recurrent respiratory tract infections. The diagnosis of CVID is an
exclusion diagnosis: according to the ESD/PAGID criteria, CVID is con-
sidered probable in patients who have marked decrease in IgG levels
(at least 2 SD below the mean for patients' age) and marked decrease
of at least one of the isotypes IgM or IgA, plus (a) onset of immunodeﬁ-
ciency after 2 years of age, (b) absent isohemagglutinins and/or poor
response to vaccines, and (c) exclusion of other deﬁned causes of
hypogammaglobulinemia such as drugs, infections, malignancy, genetic
disease, protein loss, or hypercatabolism [1,2].
CVID is a rare disease even if it is the most common primary immu-
nodeﬁciency seen in clinical practice and this is the reason why it is
called “common.” Estimated CVID incidence in Europe and North
America ranges between 1:10,000 and 1:50,000 and the prevalence
ranges from 0.073 to 0.0977 living patients per 100,000 inhabitants
[3]. These data are underestimated because most physicians are not fa-
miliar with CVID, possibly because it is generally thought that primary
immunodeﬁciencies are more common in the paediatric age, whileFig. 1.Dysregulation of B cell development, autoimmunity and recurrent infections in CVID patients.
by infectious agents (see text for explanation).
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fourth decades of life. Moreover, CVID symptoms can be quite heteroge-
neous, inducing the patients to seek for different specialists in
otorynolaringology, respiratorymedicine, gastroenterology, rheumatol-
ogy, oncology, or others. On the other hand, in about 20% of patients, the
ﬁrstmanifestation of CVID is not represented by infection but by inﬂam-
matory, autoimmune, or neoplastic diseases, hence theword “variable.”
2. CVID and immune defects
The typical defect of CVID is the failure of B lymphocytes to differen-
tiate into switched memory B cells and into plasma cells [4] (Fig. 1).
During the different steps of their maturation, B cells circulate between
splenic follicles, lymph nodes, and bonemarrow, until they undergo ap-
optosis or are activated by an antigen. This allows naive B cells to com-
plete their maturation process to switched memory B cells. Many
causes, most of them unknown, can alter this complex process.
In the last 10 years, by genome association studies and genome or
exome sequencing techniques, researchers have identiﬁed several rare
monogenic disorders with a CVID-like phenotype. Defects have been
reported in the genes encoding for B cell antigen receptor associated
complex (CD19, CD81, and CD21) [5–7], CD20 [8], inducible co-
stimulator (ICOS) [9], B cells activating factor receptor (BAFF-R) [10],
and transmembrane activator calcium-modulator and cyclophilinPossible generation of CD21low B cells frommemory B cells following recurrent stimulation
common variable immunodeﬁciency (CVID), Autoimmun Rev (2016),
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identiﬁed in less than 15% of patients [12,13].
We have reported that centroblasts (IgM + IgD–CD23–CD27–B
cells) are increased in CVID patients, while switched memory (IgM–
IgD–CD23–CD27–) B cells are decreased suggesting that one of the
defects in B cell maturation in CVID patients lies at this step of B cell
maturation [14]. Moreover, alterations of the somatic hypermutation
process both in the Ig(V) regions and in the light chains have been
described in CVID, indicating alterations in B cell maturation in the
germinal center [15].
The reduction of switched memory B cells is associated with CVID,
although it is not speciﬁc since a low number of switched memory B
cells has also been found in other primary immunodeﬁciencies [16]. In-
terestingly, switched memory B cells develop in the germinal centre of
lymph-node in a T-dependent manner. Therefore, their reduction
could depend on functional defects in both B and T cells.
Several abnormalities of T cells have also been described in CVID in-
cluding oligoclonal expansion of CD8 + T cells, decreased numbers of
CD4 + T cells [17], T cells activation defects, apoptosis and anergy
[18], impaired prolipheration in response to mitogens [19], disruption
of CD4+ and CD8+ TCR repertoire, reduction of CD31+ recent thymic
emigrants CD4+ T cells [20], reduced expression of CD40L on activated
T cells, and low levels of IL-2mRNA [21].Moreover, T lymphocytes show
an impaired secretion of several solublemediators [22], whichmay con-
tribute to the B cell differentiation failure.
Finally, the frequency and suppressive function of regulatory T cells
(Tregs) are altered in CVID patients. The expression of FOXP3 protein
and also levels of inhibitory cytokines such as IL-10 are diminished in
CVID [23]. The decrease of Treg cells is more pronounced in CVID pa-
tients with a severe decrease of switchedmemory B cells and expansion
of CD21low B cells [24].
As far as the innate immune system concerns, some reports have
shown that dendritic cells present a severely altered differentiation,
maturation, function, and reduced levels of co-stimulatory molecules
that are critical for T cell activation [25]. Moreover, a peripheral
decreased number of natural killer cells [26] and monocytes alterations
directly correlatingwith T cell activationmarkers andwith B cell imbal-
ances have been reported in CVID [27].
3. CVID and infections
The typical symptoms of CVID are infections that may involve respi-
ratory, gastrointestinal, and genitourinary tracts. Among these, themain
clinical features are represented by upper and lower airway infections,
which contribute substantially to the costs of care in these patients
[28]. Approximately a half of CVID patients have at least one episode
of pneumonia and the other half have recurrent bronchitis, sinusitis,
and/or otitis.
Despite that immunoglobulin replacement therapy, which is the
gold standard therapy of CVID, is effective in reducing the risk of infec-
tions, susceptibility to infections remains variable [29].
With regard to the causative pathogens of acute infection, bacterial
infections are the most important and frequent, particularly those
caused by Streptococcus, Haemophilus, Moraxella catharralis, Neisseria
meningitides, and Staphylococcus. Viral infections, including Rhinovirus,
Herpes zoster, and Mycoplasma spp. infections can be more frequent
andmore persistent in CVID. Pathogens that are considered opportunis-
tic such as Pneumocystis and Cytomegalovirus are less frequent [30] but
are commonly observed in CVID patients with low levels of CD4+ T
cells.
When the lung infections are severe and occur repeatedly, two dis-
tinct patterns of chronic lung disease may develop: bronchiectasis and
interstitial lung disease. Clinically, bronchiectasis is deﬁned as perma-
nent abnormal dilatation of the airway in conjunction with persistent
or recurrent bronchial sepsis [31] and its prevalence in CVID varies
greatly between centres. Bronchiectasis is more likely to affect olderPlease cite this article as: Patuzzo G, et al, Autoimmunity and infection in
http://dx.doi.org/10.1016/j.autrev.2016.07.011age groups and is associated with a history of pneumonia and a CD4+
T cell count lower than 700 cells per μl. By contrast, interstitial lung dis-
ease has been associated with increased CD4:CD8 T cell ratio, high IgM
concentration, and a history of autoimmune haemolytic anaemia or im-
mune thrombocytopenic purpura and tends to occur at younger age.
The typical pattern of interstitial lung disease in CVID is a generalised
diffuse reticular change, often with ground glass appearance at lower
lobes [32].
4. CVID and inﬂammation
Dysregulation of immune system and recurrent infections lead to
lymphoprolipheration and inﬂammatory diseases. From 8 to 20% of pa-
tients with CVID develop granulomatous inﬂammation. Virtually, any
organ can be involved, but the lung is a common site. Granulomatous
disease is frequently associated with interstitial lung disease and with
lymphocytic interstitial pneumonitis and follicular bronchiolitis [1,33].
An association between human Herpervirus type 8 infections and the
development of granulomatous and/or interstitial lung disease has
been proposed in a small group of CVIDpatients [34], but further studies
are required to better understand this association.
About half of patients with CVID has chronic diarrhoea with malab-
sorption and has histological ﬁndings suggestive of inﬂammatory bowel
disease. The most common abnormality is nodular lymphoid hyperpla-
sia, though there may be signiﬁcant lymphoid inﬁltration in the intesti-
nal lamina propria [1]. Unlike inﬂammatory bowel disease, lamina
propria lymphocytes from CVID patients are skewed toward the pro-
duction of Th1 pro-inﬂammatory cytokines such as IL-12 and INF-γ
[35]. The small bowel often presents as a celiac-like enteropathy
characterised by lymphocytic intraepithelial inﬁltration, shortness of
villi, and hyperplastic crypts. Celiac-speciﬁc antibodies are usually ab-
sent, and histological abnormalities are nonresponsive to gluten-free
diet [36].
Also, the liver may be involved in CVID. Hepatitis without evidence
of viral infection has been reported with increased blood levels of alka-
line phosphatase. Often, liver biopsy showsmild to moderate periportal
lymphocytes inﬁltration and cholestasis. Moreover, nodular regenera-
tive hyperplasia of the liver is present inmore than 80%of CVID patients,
who undergo liver biopsy [37].
5. CVID and autoimmune disease
The association between CVID and autoimmune diseases is well
recognised, since autoimmune diseases occur in approximately 20–
30% of patients with CVID. The coexistence of immunodeﬁciency and
autoimmunity appears paradoxical; while antibody production in re-
sponse to pathogens and vaccines is severely impaired or even lacking,
the generation of autoantibodies might, at the same time, be excessive.
Moreover, autoreactive B and T cells can be detected in patients with
CVID, even if speciﬁc response to antigens is impaired [37,38]. On the
other hand, considering that both innate and adaptive immune re-
sponse abnormalities occur in CVID, such as expansion of abnormal B
cell clones with altered trafﬁcking and effector functions, altered cyto-
kine expression and signalling, it is easier to understand the mecha-
nisms that lead to a breakdown of self-tolerance in CVID.
The most common autoimmune disease found in CVID patients is
immune thrombocytopenia (ITP) and autoimmune cytopenia. These
complications are frequently associated with splenomegaly; however,
hypersplenism is unable to completely explain this association and the
physiopathological link remains unclear [39]. It is important to under-
line that in more than 60% of CVID patients, the diagnosis of cytopenia
may precede by many years the detection of hypogammaglobulinemia
[40,41].
Other rheumatologic diseases, including polyarticular arthritis, like
rheumatoid arthritis, occur in 10–30% of patients with CVID. This
polyarthritis is distinct from rheumatoid arthritis because it is typicallycommon variable immunodeﬁciency (CVID), Autoimmun Rev (2016),
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frequently.
A wide spectrum of additional systemic and organ-speciﬁc au-
toimmune diseases, including systemic lupus erythematosus, per-
nicious anaemia, antiphospholipid syndrome, multiple sclerosis,
Sjögren syndrome, psoriasis, thyroiditis, uveitis, vasculitis, and primary
biliary cirrhosis has also been reported in CVID [37,38,42].
6. CVID, a crossroad between infection, inﬂammation,
and autoimmunity
The understanding of the relationship among infections, autoimmu-
nity, and inﬂammation is an interesting challenge for researchers. From
this point of view, primary immunodeﬁciencies could help us to better
understand the link between infections and autoimmunity.
The granulomas in CVID are sarcoid-like lesions. For this reason,
some authors suggested that granulomatous disease in CVID is an atyp-
ical presentation of sarcoidosis on the genetic background of immuno-
deﬁciency. On the other hand, the immunodeﬁciency can lead to a
dysregulated immune response to an unknown infectious agent,
resulting in a diffuse granulomatous reaction [33], suggesting the likeli-
hood of an infection as the original trigger. We have mentioned above
the association between Human Herpesvirus type 8 infection and granu-
lomatous disease; moreover, a case of CVID with granulomatous and
lymphoproliferative disease following an acute Toxoplasma gondii infec-
tion has been reported [43]. However, a systematic association of gran-
ulomatous lesion in CVID with particular infections has never been
reported. Overall, the pathogenesis of both sarcoidosis and granuloma-
tous lesion in CVID are not well understood; therefore, the relationship
among immunodeﬁciency, infection, and granuloma formation remains
elusive.
Recent studies have reported the involvement of human cytomega-
lovirus (HCMV) infection in the pathogenesis of chronic inﬂammation
in CVID. The prevalence of HCMV infection ranges between 40 and
95% in the general population, depending on ethnic and socioeconomic
conditions. Usually, infection in immunocompetent individuals pro-
ceeds without clinical manifestations. In immunocompromised pa-
tients, such as CVID patients, after the primary infection, virus can
persist in the host and interfere with innate and adaptive immunity,
with a pro-inﬂammatory effect [44]. Despite some alterations in T cell
phenotype and function, CVID patients have a strong CD8+ T cell re-
sponse to HCMV. Patients with evidence of HCMV exposure show a
higher prevalence of inﬂammatory disease compared with non-
exposed subjects. Furthermore, HCMV-speciﬁc CD8+ T cells are elevat-
ed in patients with CVID and inﬂammatory disease. Taken together,
these ﬁndings strengthen the hypothesis that the combination between
HCMV replication and excessive HCMV-speciﬁc CD8+ T cell response
leads to inﬂammatory disease [45]. On the other hand, HCMV infection
may be involved in the pathogenesis of some autoimmune diseases,
such as systemic sclerosis, systemic lupus erythematosus, rheumatoid
arthritis, and vasculitides, by molecular mimicry and bystander activa-
tion. Beside HCMV infection, many viruses, such as Epstein Barr Virus,
and other infectious agents, such as Salmonella spp., Staphylococcus
aureus, Streptococcus pyogenes, Mycoplasma spp., Giardia lamblia, may
trigger an autoimmune response and eventually an autoimmune
disease and all these pathogens are a frequent cause of infections in
CVID patients.
If we consider together the immune abnormalities, the recurrent in-
fections, and the chronic inﬂammation, it is easier to understand why
autoimmunity and immunodeﬁciency can coexist.
7. CD21low B cells, an elusive B cells population
Complement receptor type 2 (CD21) is expressed on B cells [46], fol-
licular dendritic cells, thymocytes, and on a subset of peripheral T cells
[47]. CD21 binds complement fragments C3d, C3dg, and iC3b that arePlease cite this article as: Patuzzo G, et al, Autoimmunity and infection in
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Fc-receptor for IgE and INF-α [48]. On B cells, CD21 forms a complex to-
gether with CD19 and CD81, which functions as a co-receptor for BCR.
After stimulation of CD21 and BCR, the threshold of B cells activation
is reduced. Therefore, CD21 functions as a bridge between the co-
receptor complex and the BCR [49].
The surface expression of CD21 on B cells depends on thematuration
stage of the cells. The majority of circulating B lymphocytes, including
naive and memory B cells, express CD21, whereas plasmablasts and
plasma cells lack or express low levels of CD21 [48].
Little is known about CD21low B cells. Probably this cell subset de-
velops from memory B-lymphocytes, because most of these cells are
switched and their BCRs contain SHM. Moreover they express surface
activationmarkers, such as CD69, CD80, and CD86, and have high levels
of mRNA encoding the homing chemokine receptors CCR1, CCR5, CCR6.
In vitro CD21low B cells show poor proliferative capacity upon BCR stim-
ulation; however, they respond to a combination of IL-2, IL-10, and
CD40L. The expansion of CD21low B cells clone is observed in some
chronic infections, including HIV, hepatitis C virus, CMV, and Plasmodi-
um spp. infection. In all these conditions, the increase of CD21low B
cells population is related to the duration of infection and to viremia.
A B cells population with characteristics similar to CD21low B cells is
described in tonsils, where B lymphocytes are constantly exposed to
foreign antigens. Taken together, these data suggest that CD21low
B cells derive from memory B cells or plasma cells after chronic
stimulation.
CD21low B cells have been described also in some autoimmune dis-
ease, such as systemic lupus eritematous, Sjögren syndrome, and rheu-
matoid arthritis [48]. Moreover, the frequency of CD21low B cells is
increased in CVID patients and correlate with splenomegaly and auto-
immunity [50].
Although CD21low B cells have been studied in several diseases, little
is known about their functions and data from the literature are contra-
dictory [51,52]. CD21low B cells appear to be in an activated state but at
the same timeexpress several inhibitory receptors. They do not prolifer-
ate in response to BCR triggering and are also prone to undergo apopto-
sis faster than CD21+B cells do, suggesting a shorter half-life. However,
these cells are able to respond to other stimuli and interact with other
cells such as T lymphocytes subsets and/or innate immune cells, either
through cell–cell contact or in response to cytokines. Moreover,
CD21low B cells may be enriched in autoreactive clones [52].
Accordingwith other studies [50], we have previously observed that
CD21low B cells are increased in CVID patients.
We therefore wanted to evaluate the levels of CD21low B cells in
patients with CVID and autoimmune thrombocytopenia, the most com-
mon autoimmune manifestation in CVID patients to better clarify the
role of this speciﬁc B cell subset in a situation characterized by
immunedeﬁciency, recurrent infections, and autoimmunity.8. Materials and methods
8.1. Patients
We studied a cohort of 10 patients (2males and 8 females,mean age
44.8 ± 12 years) affected by CVID and autoimmune trombocytopenia,
attending the Unit of Clinical Immunology at the University Hospital
of Verona. We also enrolled 10 patients with idiopathic autoimmune
thrombocytopenia, 10 patients with CVID without autoimmune dis-
eases, and 10 healthy controls. All patients with CVID fulﬁlled the
ESID/PAGID criteria for the diagnosis of the disease. At enrolment,
none of the patients had active infection or was affected by malig-
nancies. Moreover, none was treated with antineoplastic or immu-
nosuppressive drugs. All the patients affected by CVID were treated
with regular monthly infusion of immunoglobulins at the dose of
0.4 g/kg.common variable immunodeﬁciency (CVID), Autoimmun Rev (2016),
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Blood was collected in tubes containing citrate. One hundred μL of
whole blood was transferred in a 5 mL tube, lysed with ipertonic
solution to deplete red cells, and washed with PBS at 1200 rpm for
5 min. Cells were then incubated with PE anti-CD21 and APC anti-
CD19 monoclonal antibodies (Becton Dickinson, San Jose, CA, USA) for
30 min at 4 °C in the darkroom. Cells were washed again with PBS,
and 100 μL of Perfect-count Microspheres (Cytognos, Salamanca,
E) were added in order to calculate absolute cell number. Samples
were ﬁnally acquired on a FACSCanto II cytometer (Becton Dickinson)
and data analysed by FlowJo 9.7.6 software (Tree Star, Ashland, OR,
USA).
8.3. Statistical analysis
The signiﬁcance of differences was assessed by Student's t-test and
was performed using GraphPad Prism version 5 (GraphPad Software
Inc., La Jolla, CA, USA). A difference between groups with a p b 0.05
was considered statistically signiﬁcant.
9. Results
9.1. CD21low population.
We observed a statistically signiﬁcant increase in CD21low popula-
tion percentage in the three pathological groups if compared with that
of the healthy donors. Moreover, we found statistical differences be-
tween the two groups of patient affected by CVID, with patients affected
also by autoimmune thrombocytopenia displaying a higher percentage
of CD21low population.
No signiﬁcant differences were observed between patients affected
by CVID and those affected by autoimmune thrombocytopenia and
also between the two groups of patients affected by autoimmune
thrombocytopenia (Fig. 2).
10. Discussion
CD21low B cells possibly develop frommemory B cells that have un-
dergone chronic stimulation. In CVID patients, the chronic stimulation is
due to recurrent infections; therefore, it is not surprisingwhy there is an
expansion of CD21low B cells in this disease. An increased number of
CD21low B cells is observed in some autoimmune diseases, such as
Sjögren's syndrome and systemic lupus eritematous, even if the role of
CD21low B cells in the development of autoimmunity is still unclear.
The data available so far suggest that CD21low characterises a particular
B cells subset that may represent a link between infection and
autoimmunity.Fig. 2. Evaluation of CD21low B cells percentage in the four groups analysed. Differenceswere
found between controls and CVID patients (p = 0.05); controls and ITP patients (p =
0.034); CVID and CVID + ITP patients (p = 0.046); controls and CVID + ITP patients
(p = 0.006).
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http://dx.doi.org/10.1016/j.autrev.2016.07.011Our data suggest that CD21low cells are related to autoimmune
clinical manifestations but do not clarify whether they play a role in
favouring autoimmunity orwhether they are an epiphenomen. The pro-
found immune dysregulation and the recurrent stimulation of immune
system due to recurrent infections in CVID patients may cause ex-
pansion of B cells subsets with autoimmune features or allow them
to escape normal regulatory controls, which are able to eliminate
the autoimmune clones. Conﬂicting data are reported in literature:
one hypothesis suggests that CD21low cell population is characterised
by autoreactive clone subsets [52], while another one considers
CD21low cells as anergic and prone to apoptosis [53]. Our aim is to clarify
this discrepancy by sorting CD21low cells and evaluate their ability to
produce (auto)antibodies upon appropriate stimuli.Take-home messages
• The association between CVID and autoimmune diseases is well
known, since autoimmune diseases occur approximately in 20–30%
of patients affected by CVID.
• The most common autoimmune diseases found in CVID patients are
autoimmune thrombocytopenia and autoimmune cytopenia, but
rheumatoid arthritis, systemic lupus erythematosus, Sjögren syn-
drome, and primary biliary cirrhosis have also been reported.
• In the presence of autoimmune thrombocytopenia or other systemic
autoimmune or chronic inﬂammatory diseases, screening for
hypogammaglobulinemia is strongly recommended.
• Conversely, screening for autoimmune and chronic inﬂammatory
diseases is recommended in patients with CVID.
• B and T cells abnormalitiesmay contribute to development of autoim-
munity in CVID patients.
• CD21low B cells are related with autoimmune manifestation and may
represent a junction ring between infection and autoimmunity.References
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